324 - Open Access .click

Results 101 to 110 of about 298,560 (261)

Status of oncology drugs with a conditional approval: A cross‐sectional comparison of the Food and Drug Administration and Health Canada

British Journal of Clinical Pharmacology, EarlyView.
Aims This study looks at the status of the same drugs conditionally approved by the Food and Drug Administration and Health Canada for the same oncology indication. Methods Lists of oncology drugs with a conditional approval from the Food and Drug Administration and Health Canada were generated and drug pairs with the same indication were matched ...
Joel Lexchin
wiley +1 more source

Cost‐utility analysis of nusinersen–risdiplam switch in patients with spinal muscular atrophy in Croatia: A discrete event simulation model

British Journal of Clinical Pharmacology, EarlyView.
Introduction In recent years, the treatment of spinal muscular atrophy (SMA), a rare disease, has significantly progressed, improving patients' survival and overall quality of life. However, current SMA treatments are expensive, and some (nusinersen) are very inconvenient for patients.
Andrej Belančić +4 more
wiley +1 more source

Band 1, 324 (Sammlung Friedlaender) [PDF]

BAND 1, 324 (SAMMLUNG FRIEDLAENDER) Band 1, 324 (Sammlung Friedlaender) (Public Domain ...

core

Evaluating the (comparative) safety profile of the novel oral polio vaccine type 2 using individual case safety reports in VigiBase

British Journal of Clinical Pharmacology, EarlyView.
Aim Novel oral polio vaccine type 2 (nOPV2) was used under the WHO emergency use listing for circulating vaccine‐derived polio virus (cVDPV) outbreaks from 2021 to 2023. We assessed nOPV2 adverse events following immunization (AEFIs) and compared its safety profile to other vaccines using VigiBase.
Comfort Kunak Ogar +6 more
wiley +1 more source

Band 4, 324 (Sammlung Friedlaender) [PDF]

BAND 4, 324 (SAMMLUNG FRIEDLAENDER) Band 4, 324 (Sammlung Friedlaender) (Public Domain ...

core

Long non-coding RNA LINC-PINT: emerging clinical significance and molecular mechanisms in knee osteoarthritis. [PDF]

J Orthop Surg Res
Zhou S, Zhang Y, Jiang S, Zhang C.
europepmc +1 more source

A phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of PF‐07261271 in healthy participants

British Journal of Clinical Pharmacology, EarlyView.
Aim There is an unmet need for more effective therapies in inflammatory bowel disease (IBD). A single drug that blocks multiple distinct pathogenic pathways may offer therapeutic benefit superior to current monotherapies. PF‐07261271, a bispecific antibody targeting both the p40 subunit of interleukin‐12/23 and tumour necrosis factor‐like cytokine 1A ...
Srividya Neelakantan +11 more
wiley +1 more source

Band 6, 324 (Sammlung Friedlaender) [PDF]

BAND 6, 324 (SAMMLUNG FRIEDLAENDER) Band 6, 324 (Sammlung Friedlaender) (Public Domain ...

core

Digital Health Technology Use Among Rehabilitation Professionals in China: Multi-Province Cross-Sectional Survey. [PDF]

J Med Internet Res
Duan S, Wang ZR, Chen X, Ni G.
europepmc +1 more source

Risk of venous thromboembolism after SARS‐CoV‐2 vaccination—Evidence from genome‐wide association study and population‐based observational study

British Journal of Clinical Pharmacology, EarlyView.
Aim We aimed to investigate whether genetic variation is associated with venous thromboembolism after immunization with SARS‐CoV‐2 vaccines. Methods We conducted a genome‐wide association study (GWAS) on cases of venous thromboembolism within 42 days after SARS‐CoV‐2 vaccination, recruited from reports of adverse drug reactions sent to the Swedish ...
Sofia Attelind +7 more
wiley +1 more source